MCB Stock Analysis: Metropolitan Bank Holding | NYSE
Banks - Regional | NYSE, USA | Market Cap: 1.157m USD | 12M Return: 34.7% | US5917741044 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 15.2M
EPS Trend: 64.1%
Qual. Beats: 0
Rev. Trend: 31.1%
Qual. Beats: 0
Warnings
Tailwinds
No distinct edge detected
Seasonality 9 years of data, until 10/2026
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, ≥40 worth a closer look and ≥60 is strong.
Metropolitan Bank Holding Corp. (NYSE: MCB) is the bank holding company for Metropolitan Commercial Bank, providing a broad range of business, commercial, and retail banking products and services. Its deposit offerings include checking, savings, term deposits, money market accounts, and non-interest-bearing demand deposits, while its lending products span commercial real estate, multi-family, construction, one-to-four-family real estate, commercial and industrial loans, consumer loans (including purchased student loans), acquisition and renovation loans, owner-occupied property loans, equity refinance loans, working capital lines of credit, trade finance, letters of credit, and term loans. The company also delivers cash management, online and mobile banking, ACH, remote deposit capture, debit card programs, and merchant services to small businesses, middle-market enterprises, public entities, and individuals.
Originally incorporated in 1997 as Metbank Holding Corp. and renamed in January 2007, MCB is headquartered in New York, NY, and went public on the NYSE in November 2017. Classified within the Financials sector under the Regional Banks sub-industry, the company operates in a competitive U.S. community and commercial banking segment where institutions typically generate revenue through net interest margins on loans and deposits, supplemented by fee-based services such as cash management and merchant processing. With a small-cap market capitalization, MCB competes against both larger regional banks and other community-focused lenders serving the New York metropolitan area.
- Net interest margin compresses as deposit costs outpace loan yield growth
- Commercial real estate loan portfolio faces refinancing risk amid higher rates
- Deposit growth slows as competition for low-cost funding intensifies
| Net Income: 111.9m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.01 > 0.02 and ΔFCF/TA -0.32 > 1.0 |
| NWC/Revenue: -1.51k% < 20% (prev -1.20k%; Δ -309.1% < -1%) |
| CFO/TA 0.01 > 3% & CFO 136.5m > Net Income 111.9m |
| Net Debt (-1.70b) to EBITDA (76.3m): -22.26 < 3 |
| Current Ratio: 0.21 > 1.5 & < 3 |
| Outstanding Shares: last quarter (12.6m) vs 12m ago 18.73% < -2% |
| Gross Margin: 53.33% > 18% (prev 51.18%; Δ 2.14% > 0.5%) |
| Asset Turnover: 4.92% > 50% (prev 6.20%; Δ -1.29% > 0%) |
| Interest Coverage Ratio: 0.43 > 6 (EBIT TTM 87.2m / Interest Expense TTM 201.2m) |
| A: -0.70 (Total Current Assets 1.73b - Total Current Liabilities 8.32b) / Total Assets 9.47b |
| B: 0.06 (Retained Earnings 523.1m / Total Assets 9.47b) |
| C: 0.01 (EBIT TTM 87.2m / Avg Total Assets 8.85b) |
| D: 0.11 (Book Value of Equity 974.7m / Total Liabilities 8.50b) |
| Altman-Z'' = -4.19 = D |
As of November 20, 2026, the stock is trading at USD 92.58 with a total of 189,370 shares traded. Over the past week, the price has changed by -4.66%, over one month by +7.44%, over three months by +1.70% and over the past year by +34.66%.
Current recommended Stop Loss: 89.60 (which is 3.2% or 1.2 ATR below the current price).
Metropolitan Bank Holding has received a consensus analysts rating of 4.00. Therefore, it is recommended to buy MCB.
- StrongBuy: 1
- Buy: 1
- Hold: 1
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 108.3 | 17% |
P/E Trailing = 9.8288
P/S = 3.2902
P/B = 1.2125
Revenue TTM = 435.2m USD
EBIT TTM = 87.2m USD
EBITDA TTM = 76.3m USD
Long Term Debt = 15.9m USD (from longTermDebt, last quarter)
Short Term Debt = 5.38m USD (from shortTermDebt, last fiscal year)
Debt = 36.5m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -1.70b USD (calculated: Debt 36.5m - CCE 1.73b)
Enterprise Value = 1.16b USD (floored to Market Cap, CCE > MCap+Debt)
Interest Coverage Ratio = 0.43 (Ebit TTM 87.2m / Interest Expense TTM 201.2m)
EV/FCF = 9.09x (Enterprise Value 1.16b / FCF TTM 127.2m)
FCF Yield = 11.00% (FCF TTM 127.2m / Enterprise Value 1.16b)
FCF Margin = 29.24% (FCF TTM 127.2m / Revenue TTM 435.2m)
Net Margin = 25.73% (Net Income TTM 111.9m / Revenue TTM 435.2m)
Gross Margin = 53.33% ((Revenue TTM 435.2m - Cost of Revenue TTM 203.1m) / Revenue TTM)
Gross Margin QoQ = 63.59% (prev none%)
Tobins Q-Ratio = 0.12 (Enterprise Value 1.16b / Total Assets 9.47b)
Interest Expense / Debt = 550.8% (Interest Expense 201.2m / Debt 36.5m)
Taxrate = 29.79% (47.5m / 159.4m)
NOPAT = 61.2m (EBIT 87.2m * (1 - 29.79%))
Current Ratio = 0.21 (Total Current Assets 1.73b / Total Current Liabilities 8.32b)
Debt / Equity = 0.04 (Debt 36.5m / totalStockholderEquity, last quarter 974.7m)
Debt / EBITDA = -22.26 (Net Debt -1.70b / EBITDA 76.3m)
Debt / FCF = -13.35 (Net Debt -1.70b / FCF TTM 127.2m)
Total Stockholder Equity = 908.6m (last 4 quarters mean from totalStockholderEquity)
RoA = 1.26% (Net Income 111.9m / Total Assets 9.47b)
RoE = 12.32% (Net Income TTM 111.9m / Total Stockholder Equity 908.6m)
RoCE = 9.43% (EBIT 87.2m / Capital Employed (Equity 908.6m + L.T.Debt 15.9m))
RoIC = 5.40% (NOPAT 61.2m / Invested Capital 1.13b)
WACC = 7.61% (E(1.16b)/V(1.19b) * Re(7.85%) + (debt cost/tax rate unavailable))
Discount Rate = 7.85% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 36.48 | Cagr: 5.27%
[DCF] Terminal Value 74.43% ; FCFF base≈131.1m ; Y1≈123.9m ; Y5≈116.2m
[DCF] Fair Price = 289.2 (EV 1.83b - Net Debt -1.70b = Equity 3.53b / Shares 12.2m; r=8.35% [WACC [floored]]; 5y FCF grow -7.03% → 2.50% )
EPS Correlation: 64.07 | EPS CAGR: 11.09% | SUE: 0.29 | # QB: 0
Revenue Correlation: 31.10 | Revenue CAGR: 3.34% | SUE: 0.54 | # QB: 0
EPS current Quarter (2027-03-31): EPS=2.53 | Chg30d=-1.69% | Revisions=-40% | Analysts=2
EPS current Year (2026-12-31): EPS=9.64 | Chg30d=+2.07% | Revisions=+40% | GrowthEPS=+46.6% | GrowthRev=+21.8%
EPS next Year (2027-12-31): EPS=11.08 | Chg30d=-2.90% | Revisions=-17% | GrowthEPS=+14.9% | GrowthRev=+11.6%
[Analyst] Revisions Ratio: -10% (up=3, down=4)